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Both a low estimated glomerular filtration rate (eGFR) and
albuminuria are known risk factors for end-stage renal
disease (ESRD). To determine their joint contribution to ESRD
and other kidney outcomes, we performed a meta-analysis of
nine general population cohorts with 845,125 participants
and an additional eight cohorts with 173,892 patients, the
latter selected because of their high risk for chronic kidney
disease (CKD). In the general population, the risk for ESRD
was unrelated to eGFR at values between 75 and 105ml/min
per 1.73m2 but increased exponentially at lower levels.
Hazard ratios for eGFRs averaging 60, 45, and 15 were 4, 29,
and 454, respectively, compared with an eGFR of 95, after
adjustment for albuminuria and cardiovascular risk factors.
Log albuminuria was linearly associated with log ESRD risk
without thresholds. Adjusted hazard ratios at albumin-to-
creatinine ratios of 30, 300, and 1000mg/g were 5, 13, and
28, respectively, compared with an albumin-to-creatinine
ratio of 5. Albuminuria and eGFR were associated with ESRD,
without evidence for multiplicative interaction. Similar
associations were found for acute kidney injury and
progressive CKD. In high-risk cohorts, the findings were
generally comparable. Thus, lower eGFR and higher
albuminuria are risk factors for ESRD, acute kidney injury and
progressive CKD in both general and high-risk populations,
independent of each other and of cardiovascular risk factors.
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This is the third in a series of four manuscripts to report
the results of collaborative meta-analyses of estimated GFR
(eGFR) and albuminuria on outcomes of chronic kidney
disease (CKD) undertaken by the CKD Prognosis Con-
sortium. These analyses were undertaken in conjunction
with the 2009 Controversies Conference sponsored by Kidney
Disease Improving Global Outcomes (KDIGO) to evaluate
the current definition and classification of CKD and
proposed alternatives.1 The report of the Consensus
Conference is included in this issue of Kidney International.2
Widespread implementation of the definition and classi-
fication of CKD, as proposed by Kidney Disease Outcomes
Quality Initiative (KDOQI) in 2002 and subsequently
endorsed by KDIGO in 2004, has promoted increased
attention to CKD in clinical practice, research, and public
health.3–6 It has also generated substantial debate about the
appropriateness of recommending the same GFR thresholds
for people of all ages, the optimal level of albuminuria for
diagnosing kidney damage, and about the value of the 5-stage
classification system based on eGFR without consideration of
albuminuria.7–11 It was the position of KDOQI and KDIGO
that a comprehensive analysis of mortality and kidney
outcomes according to eGFR and albuminuria was needed
to answer key questions underlying the debate.1,2
Until recently, most of the data on kidney outcomes were
from studies of patients with later stages of CKD rather than
from general population cohorts or cohorts at increased risk for
CKD.12–14 Reports from the general population and high-risk
cohorts focused mainly on all-cause and cardiovascular
mortality,15–20 with fewer data available on kidney out-
comes.19–22 In this manuscript, we describe a collaborative
meta-analysis of nine general population and eight high-risk
cohorts. The outcomes reported in this manuscript include
kidney failure treated by dialysis or transplantation (end-stage
renal disease (ESRD)) or coded on the death certificate. In
addition, we also included acute kidney injury, because it is
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increasingly recognized as a major cause for23 and consequence
of CKD,24 and kidney disease progression, based on fast eGFR
decline (progressive CKD), because of its clinical importance
and potential to lead to ESRD or other complications.
Other papers in this series deal with all-cause and
cardiovascular mortality in general population cohorts and
high-risk cohorts.25,26 This report describes the kidney
outcomes from these cohorts. A fourth manuscript reports
mortality and kidney outcomes in CKD cohorts.27 A priori
we hypothesized that both eGFR and albuminuria would be
associated with these outcomes, independent of traditional
cardiovascular risk factors and independent of each other,
and despite inclusion of diverse study populations.
RESULTS
Study and population characteristics
Of the nine general population cohorts (845,125 subjects),
five had data on albumin-to-creatinine ratio and four on
dipstick. Of the eight high-risk cohorts (173,892 subjects),
five had data on albumin-to-creatinine ratio and three
on dipstick (Table 1). Acronyms and abbreviations for studies
included in the current report are given in Supplementary
Web appendix Table S1 online. Subjects in the high-risk
cohorts were more often male, and these cohorts had a higher
prevalence of cardiovascular risk factors than did the general
population cohorts. Moreover, the high-risk cohorts gen-
erally had a lower eGFR and higher albumin-to-creatinine
ratio. Not all cohorts had data on all kidney outcomes. There
were a total of 2179, 4939, and 11,144 participants who
developed ESRD, acute kidney injury, and progressive CKD,
respectively. The incidence rates for the kidney outcomes
were two- to sixfold higher in the high-risk cohorts compared
with the general population cohorts (1.83 versus 0.31 for
ESRD, 4.88 versus 2.21 for acute kidney injury, and 18.44
versus 7.55 events per 1000 person-years for progressive
CKD, respectively) (Supplementary Web appendix Tables
S1–4 online, respectively). A total of 13.7% of the subjects of
general population cohorts with albumin-to-creatinine ratio
data had CKD according to the current definition (eGFR
o60ml/min per 1.73m2 or albumin-to-creatinine ratio
X30mg/g) (Supplementary Web appendix Table S5 online).
This subgroup accounted for 88.6% of ESRD events
(Supplementary Web appendix Table S6 online), 61.5% of
acute kidney injury events (Supplementary Web appendix
Table S7 online), and 76.7% of subjects with progressive CKD
(Supplementary Web appendix Table S8 online).
Independent continuous associations of eGFR and
albuminuria with kidney outcomes
Pooled hazard ratios of ESRD according to eGFR and
albuminuria adjusted for each other and covariates in the
general population cohorts and the high-risk cohorts are
shown in Figure 1. ESRD risk was relatively constant between
an eGFR of 75 and 120ml/min per 1.73m2, and was
exponentially greater at lower eGFR. In the general popula-
tion cohorts, eGFR risk association with ESRD showed
hazard ratios at eGFR 60, 45, and 15ml/min per 1.73m2 of
3.69 (2.36–5.76), 29.3 (19.5–44.1), and 454.9 (112.4–1840.2),
respectively. The relationship of albumin-to-creatinine ratio to
the relative risk of ESRD was monotonic on the log–log scale,
without threshold effects. As compared with albumin-to-
creatinine ratio 5mg/g, hazard ratios for ESRD at albumin-to-
Table 1 | Characteristics of included studies
N
Age,
year
Male,
%
Black,
%
CVD,
%
HT,
%
HC,
%
DM,
%
Smoking,
%
eGFR, ml/min
per 1.73m2
ACR,
mg/g
FU,
Year
ESRD,
n
AKI,
n
pCKD,
n
General population cohorts with ACR data 147 427 173
ARIC 11,408 62.8 44.2 22.2 8.6 47.6 34.5 16.7 14.9 82.5 3.7 8.0 92 363 —
AusDiab 11,240 51.5 44.9 0 8.3 32.7 70.6 8.4 15.5 78.9 4.9 5.0 — — 72
CHS 3230 78.0 40.2 15.9 29.3 50.1 31.0 14.7 7.6 79.4 8.8 7.6 — 64 —
HUNT2 9525 62.0 44.8 0 22.5 82.5 61.3 17.6 19.7 83.8 7.5 10.5 55 — —
MESA 6728 62.2 47.2 27.5 0.0 44.8 9.0 12.6 13.0 81.2 5.3 4.7 — 101
General population cohorts with dipstick data 713 3438 4624
AKDN UDIP 690,680 47.4 45.1 NA 1.8 20.2 NA 6.1 NA 80.9 — 2.3 478 3438 4475
Beaver Dam 4926 62.0 43.9 0 14.8 50.5 53.9 10.3 19.7 76.2 — 11.6 — — 149
Okinawa 83 6659 51.9 39.5 NA NA NA NA 3.8 NA 73.9 — 16.8 61 — —
Okinawa 93 93,234 54.6 43.6 NA NA NA NA 4.7 NA 77.3 — 6.9 174 — —
High-risk cohorts with ACR data 740 1074 4935
ADVANCE 11,140 65.8 57.5 NA 32.2 82.2 33.0 100 15.1 78.2 15.9 4.8 59 — 822
AKDN ACR 67,406 55.5 56.8 NA 5.0 46.8 NA 49.0 NA 76.8 11.1 2.3 191 1013 1572
ONTARGET 25,620 66.4 73.3 2.5 92 NA* NA* 37.5 12.6 73.6 52.2 4.5 162 61 1914
Pima 6341 26.4 45.4 0 NA 12.9 4.2 20.4 27.8 144 11.9 13.5 328 — 273
TRANSCEND 5926 66.9 57 1.8 92.5 NA* NA* 35.7 9.8 71.7 25.3 4.6 — — 354
High-risk cohorts with dipstick data 579 — 1412
CARE 4098 58.6 87.2 3.2 100 82.9 79.0 14.2 16.1 71.9 — 4.8 — — 124
Hawaii 40,210 59.0 50.4 NA 17.0 NA NA 48.0 13.6 71.5 — 2.4 331 — 1288
MRFIT 12,851 46.2 100 31.3 0.0 62.3 57.1 3.1 63.7 79.7 — 21.6 248 — —
Abbreviations: ACR, albumin-to-creatinine ratio; AKI, acute kidney injury; CVD, cardiovascular disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; ESRD,
end-stage renal disease; FU, duration of follow-up; HC, hypercholesterolemia; HT, hypertension; NA, not available; pCKD, progressive chronic kidney disease.
NA* in ONTARGET and TRANSCEND, respectively, a history of hypertension was reported by 69 and 76%, and statin use by 62 and 55%.
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creatinine ratios of 30, 300 and 1000mg/g were 4.87
(2.30–10.3), 13.4 (5.49–32.7), and 28.4 (14.9–54.2), respectively.
These patterns for ESRD in the high-risk cohorts were similar
to the general population cohorts (Figure 1). The patterns for
acute kidney injury and progressive CKD were generally similar
to the patterns for ESRD, although less steep (Supplementary
Web appendix Figures S1, S2 online).
Interactions
The multiplicative interaction between eGFR and albumi-
nuria was significant for ESRD in only 1 out of 8 cohorts, for
acute kidney injury in 3 out of 5 cohorts, and for progressive
CKD in 4 out of 11 cohorts (Supplementary Web appendix
Table S9 online). Significant interaction between eGFR and
age was found for ESRD in only 1 out of 9 cohorts, for acute
kidney injury in 3 out 5 cohorts, and for progressive CKD in
4 out of 11 cohorts (Supplementary Web appendix Table S9
online). Age interactions tended to show lower hazard ratios
at older age, but a similar pattern of the associations of eGFR
and albumin-to-creatinine ratio with the various kidney
outcomes (Supplementary Web appendix Tables S10–12
online). The eGFR albumin-to-creatinine ratio interaction
can be visually assessed in graph 2. At low eGFR, the hazard
ratio of higher albumin-to-creatinine ratio tended to be less
than at high eGFR for ESRD as well as for acute kidney
injury, but not for progressive CKD.
Joint associations of eGFR and albuminuria with kidney
outcomes
As the albumin-to-creatinine ratio and the dipstick cohorts
showed similar relationships between eGFR and albuminuria
with ESRD, these two type of cohorts were combined to
increase power for investigation of the joint associations of
eGFR and albuminuria with kidney outcomes, both in
general population and in high-risk cohorts (Supplementary
Web appendix Figure S3 online). Table 2 shows unadjusted
incidence rates of the three kidney outcomes for general
population cohorts. Pooled hazard ratios/odds ratios for
ESRD, acute kidney injury, and progressive CKD of the 21
categories of eGFR and albuminuria for the general
population cohorts are shown in Tables 3 and 4. Low eGFR
showed a similar association with risk across all levels of
albuminuria, and high albuminuria showed a similar
association with risk across all levels of eGFR, indicating
multiplicative independent risk for kidney outcomes. At
severely reduced eGFR values (15–29ml/min per 1.73m2),
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Figure 1 |Pooled hazard ratios (95% confidence interval) for
ESRD according to spline eGFR (upper panels) and albumin-
to-creatinine ratio (lower panels), adjusted for each other and
for age, sex, and cardiovascular risk factors (continuous
analyses). Reference categories are eGFR 95ml/min per 1.73m2
and albumin-to-creatinine ratio 5mg/g or dipstick negative or
trace. Left panels show results for general population cohorts,
and right panels for high-risk cohorts. Dots represent statistical
significance, triangles represent non-significance, and shaded
areas are 95% confidence interval. ACR, albumin-to-creatinine
ratio; AKI, acute kidney injury; eGFR, estimated glomerular
filtration rate; ESRD, end-stage renal disease; GP cohorts, general
population cohorts; HR, hazard ratio; HR cohorts, high-risk
cohorts.
Table 2 | General population cohorts
Albumin-to-creatinine ratio (mg/g) or dipstick (classes)
o10
Negative
10–29
Trace
30–299
(1+)
X300
(X2+) All
ESRD
eGFR ml/min per 1.73m2
4105 0.13 0.75
90–104 0.04 0.05 0.57 0.06
75–89 0.11 2.35
60–74 0.27 2.66
45–59 0.12 0.77 1.44 5.13 0.34
30–44 1.03 1.55 9.15 27.07 4.02
15–29 9.05 19.50 37.69 128.4 42.99
All 0.09 1.61 14.9 0.31
Acute kidney injury
eGFR ml/min per 1.73m2
4105 3.55 7.57
90–104 0.98 3.04 5.73 1.14
75–89 3.45 5.86
60–74 6.46 13.77
45–59 4.73 13.10 21.40 36.08 6.48
30–44 24.49 42.53 52.09 76.62 32.65
15–29 69.66 65.82 92.93 109.6 81.37
All 1.69 10.15 26.26 2.21
Progressive CKD
eGFR ml/min per 1.73m2
4105 1.56 12.60
90–104 2.02 2.72 7.02 2.48
75–89 5.25 25.21
60–74 16.80 47.50
45–59 23.91 31.91 63.61 135.1 28.78
30–44 37.53 54.60 82.27 177.5 55.37
15–29 33.12 55.36 82.08 178.9 77.14
All 5.62 25.93 89.59 7.55
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration
rate; ESRD, end-stage renal disease.
Unadjusted incidence rates (per 1000 patient-years) for ESRD, acute kidney injury,
and progressive CKD. Shaded areas make up the combined reference groups.
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Table 3 | General population cohorts
Albumin-to-creatinine ratio (mg/g) or dipstick (classes)
o10 Negative 10–29 Trace 30–299 (1+) X300 (X2+) All
ESRD
eGFR ml/min per 1.73m2
4105 7.8 (1.7–35.9) 18.1 (4.3–75.9)
90–104 Ref 11.3 (2.7–47.7) 19.7 (5.8–66.5) Ref
75–89 3.8 (1.2–12.3) 48.1 (28.1–82.3)
60–74 7.4 (3.6–15.2) 67.2 (40.1–113)
45–59 5.2 (3.3–8.0) 21.8 (12.0–39.6) 40.3 (23.5–69.2) 147 (98.7–219) 9.6 (7.0–13.2)
30–44 55.5 (36.0–85.6) 74.1 (29.3–187) 293 (199–433) 763 (563–1035) 98.1 (61.8–156)
15–29 433 (239–787) 1044 (524–2077) 1056 (572–1948) 2286 (1114–4695) 573 (241–1362)
All Ref 12.0 (7.9–18.1) 72.1 (43.0–121)
Acute kidney injury
eGFR ml/min per 1.73m2
4105 2.7 (0.9–8.5) 8.4 (5.1–13.8)
90–104 Ref 2.4 (1.1–5.2) 5.8 (3.7–9.2) Ref
75–89 2.5 (1.9–3.4) 4.1 (2.8–5.9)
60–74 3.3 (2.6–4.1) 6.4 (5.0–8.2)
45–59 2.2 (2.0–2.5) 4.9 (3.3–7.3) 6.3 (4.8–8.4) 5.9 (2.4–14.5) 2.6 (2.2–3.1)
30–44 7.3 (6.5–8.2) 10.2 (5.9–17.5) 12.4 (10.2–15.2) 19.6 (16.5–23.2) 7.9 (7.1–8.7)
15–29 16.8 (14.0–20.2) 16.8 (11.3–25.1) 21.4 (16.5–27.8) 28.8 (23.7–35.1) 16.7 (14.7–18.9)
All Ref 2.5 (1.7–3.7) 6.0 (4.5–8.0)
Progressive CKD
eGFR ml/min per 1.73m2
4105 0.7 (0.7–0.8) 3.0 (0.4–23.7)
90–104 Ref 0.9 (0.4–2.1) 3.3 (0.5–23.3) Ref
75–89 1.9 (0.6–5.6) 5.0 (0.9–27.1)
60–74 3.2 (1.4–7.5) 8.1 (5.2–12.8)
45–59 3.1 (1.6–6.0) 4.0 (1.9–8.8) 9.4 (3.7–23.7) 56.6 (4.2–767.6) 3.9 (1.9–7.8)
30–44 3.0 (1.2–7.5) 19.1 (19.0–19.2) 14.9 (2.8–78.5) 22.2 (4.8–103.6) 3.7 (1.1–12.3)
15–29 4.0 (3.9–4.0) 11.7 (11.6–11.9) 21.0 (4.5–99.5) 7.7 (2.9–20.6) 7.9 (3.0–21.2)
All Ref 3.1 (2.5–3.8) 11.2 (5.8–21.5)
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; Ref, reference.
Pooled adjusted hazard ratios (95% confidence interval) for ESRD and acute kidney injury, and pooled adjusted odds ratios (95% confidence interval) for progressive
CKD. Shaded areas make up the combined reference groups.
Table 4 | General population cohorts
Albumin-to-creatinine ratio (mg/g) or dipstick (classes)
o10 Negative 10–29 Trace 30–299 (1+) X300 (X2+) All
ESRD, younger than 65 years of age
eGFR ml/min per 1.73m2
4105 12.4 (2.3–66.8) 28.6 (6.5–127)
90–104 Ref 14.2 (3.3–61.0) 13.8 (1.9–101.2) Ref
75–89 5.8 (1.4–24.2) 65.2 (37.3–114)
60–74 5.6 (2.0–15.7) 87.3 (32.3–236)
45–59 3.1 (1.1–8.3) 31.8 (14.3–70.5) 55.4 (29.6–103) 261 (112–610) 9.5 (5.6–15.9)
30–44 101 (54.8–187) 293 (69.3–1236) 272 (107–693) 828 (443–1545) 110 (49.6–245)
15–29 999 (493–2023) 3897 (1717–8845) 2398 (1247–4609) 5081 (2736–9435) 1281 (556–2952)
All Ref 13.7 (8.8–21.3) 124 (60.2–257)
ESRD, older than 65 years of age
eGFR ml/min per 1.73m2
4105 0.0 (0.0–N) 0.0 (0.0–N)
90–104 Ref 0.0 (0.0–N) 0.0 (0.0–N) Ref
75–89 0.0 (0.0–N) 0.0 (0.0–N)
60–74 6.6 (1.6–27.2) 18.8 (5.3–67.1)
45–59 3.4 (1.6–7.2) 9.6 (3.8–24.4) 16.4 (5.9–45.9) 41.4 (8.0–215) 4.5 (3.0–6.8)
30–44 11.5 (6.0–22.1) 18.1 (3.83–85.9) 90.8 (48.3–171) 268 (157–458) 42.1 (28.7–61.7)
15–29 131 (62.7–274) 115 (33.8–389) 413 (222–768) 1071 (645–1779) 186 (92.9–372)
All Ref 10.3 (6.0–17.8) 47.5 (27.2–82.9)
Abbreviations: eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; Ref, reference.
Pooled adjusted hazard ratios (95% confidence interval) for ESRD subdivided for age groups o65 and 465 years of age. Shaded areas make up the combined
reference groups.
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the risk associated with higher albuminuria was attenuated.
The patterns were much steeper (that is, risk increased more
rapidly with increasing albuminuria) for ESRD than for acute
kidney injury and progressive CKD (Tables 3 and 4). Figure 2
shows the continuous analyses (allowing interaction) of the
hazard ratios/odds ratios of eGFR and albuminuria for ESRD,
acute kidney injury, and progressive CKD, respectively.
Similar data are given for cohorts at high risk for CKD
(Tables 5, 6 and 7). The patterns for ESRD were less steep in
the high-risk cohorts (Table 6) compared with the general
population cohorts (Table 3), whereas the patterns for acute
kidney injury and progressive CKD were similar in the
general population cohorts and high-risk cohorts.
Joint associations of eGFR and albuminuria with kidney
outcomes per age group
The overall incidence rates for the kidney outcomes were three-
to ninefold higher in the subgroup of subjects with age X65
years compared with the subgroup with age o65 years
(Supplementary Web appendix Tables S2–4 online, respectively).
Pooled hazard ratios for ESRD of the 21 categories of eGFR and
albuminuria according to age group are shown in Table 4 for
the general population cohorts and in Table 5 for the high-risk
cohorts. The general pattern of higher risk for a lower eGFR
independent of albuminuria level and of a higher albuminuria
independent of eGFR level was observed in both age groups.
However, in general, relative hazards were smaller among
participants X65 years of age than among participants o65
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Figure 2 |Pooled adjusted hazard ratios or odds ratios
(95% confidence interval) for ESRD (upper panels), acute
kidney injury (middle panels), and progressive chronic kidney
disease (lower panels) according to eGFR and albuminuria
based on continuous models with eGFR (splines), albuminuria
(log-linear albumin-to-creatinine ratio or categorical dipstick),
and their interaction terms. Hazard ratios are adjusted for age,
sex, and cardiovascular risk factors. Reference category is eGFR
95ml/min per 1.73m2 plus albumin-to-creatinine ratio 5mg/g or
dipstick negative or trace. Left panels shows results for general
population cohorts, and right panels for high-risk cohorts.
Dots represent statistical significance, triangles represent non-
significance, and shaded areas are 95% confidence interval. In this
figure, albuminuria is treated categorically. Black lines and blue
shading represent an albumin-to-creatinine ratio o30mg/g or
dipstick negative or trace, green lines and green shading an
albumin-to-creatinine ratio 30–299mg/g or dipstick 1þ , and red
lines and red shading an albumin-to-creatinine ratio X300mg/g
or dipstick X2þ . AKI, acute kidney injury; eGFR, estimated
glomerular filtration rate; ESRD, end-stage renal disease; GP
cohorts, general population cohorts; HR, hazard ratio; HR cohorts,
high-risk cohorts; OR, odds ratio; pCKD, progressive chronic
kidney disease.
Table 5 | High-risk cohorts
Albumin-to-creatinine ratio (mg/g) or dipstick (classes)
o10
Negative
10–29
Trace
30–299
(1+)
X300
(X2+) All
ESRD
eGFR ml/min per 1.73m2
4105 1.22 6.52
90–104 0.22 0.39 5.00 0.45
75–89 0.30 4.56
60–74 0.36 7.77
45–59 0.25 0.36 1.65 13.38 1.44
30–44 1.56 2.42 4.33 29.80 7.35
15–29 1.57 12.78 20.93 133.0 60.98
All 0.31 1.41 25.72 1.83
Acute kidney injury
eGFR ml/min per 1.73m2
4105 2.99 5.54
90–104 1.41 3.35 5.43 2.25
75–89 3.09 9.92
60–74 6.06 13.73
45–59 2.28 8.00 13.42 29.03 8.07
30–44 11.20 17.76 36.70 52.09 27.63
15–29 25.74 48.66 69.90 104.7 73.94
All 2.33 9.08 26.59 4.88
Progressive CKD
eGFR ml/min per 1.73m2
4105 4.43 27.52
90–104 5.51 5.75 14.44 7.97
75–89 8.59 30.90
60–74 19.01 68.77
45–59 23.75 37.88 57.67 147.1 43.84
30–44 33.55 35.35 64.99 160.3 65.65
15–29 12.44 43.16 58.43 209.3 103.3
All 10.40 25.96 105.0 18.44
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration
rate; ESRD, end-stage renal disease.
Unadjusted incidence rates (per 1000 patient-years) for ESRD, acute kidney injury,
and progressive CKD. Shaded areas make up the combined reference groups.
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Table 6 | High-risk cohorts
Albumin-to-creatinine ratio (mg/g) or dipstick (classes)
o10 Negative 10–29 Trace 30–299 (1+) X300 (X2+) All
ESRD
eGFR ml/min per 1.73m2
4105 1.1 (0.8–1.6) 2.0 (0.9–4.5)
90–104 Ref 2.3 (1.0–5.4) 10.0 (2.1–47.2) Ref
75–89 1.7 (0.9–3.3) 17.3 (4.0–74.9)
60–74 3.1 (1.8–5.3) 32.2 (11.8–87.8)
45–59 2.7 (1.7–4.3) 3.8 (1.9–7.5) 14.5 (6.3–33.1) 55.5 (17.9–173) 5.7 (1.7–4.3)
30–44 23.4 (11.0–49.5) 33.4 (12.9–86.4) 56.0 (20.0–157) 139.8 (35.6–549) 27.4 (11.0–49.5)
15–29 32.6 (4.3–249) 308 (97.0–979) 387 (86.9–1725) 462.7 (31.6–6780) 166 (52.4–524)
All Ref 4.3 (2.6–7.1) 38.1 (15.6–93.5)
Acute kidney injury
eGFR ml/min per 1.73m2
4105 2.2 (1.2–4.2) 3.8 (1.2–12.0)
90–104 Ref 2.1 (1.3–3.4) 3.4 (1.4–8.3) Ref
75–89 1.8 (1.3–2.5) 5.2 (3.2–8.6)
60–74 2.8 (1.4–5.6) 6.3 (4.3–9.2)
45–59 1.7 (1.2–2.5) 3.5 (2.6–4.7) 6.6 (5.2–8.5) 13.0 (9.7–17.3) 3.0 (2.5–3.5)
30–44 8.0 (5.4–11.8) 7.5 (5.3–10.6) 14.3 (11.2–18.3) 26.9 (12.3–58.8) 10.6 (5.2–21.9)
15–29 12.3 (5.4–27.8) 1.6 (0.0–N) 25.3 (18.2–35.3) 13.7 (0.0–N) 16.8 (13.5–20.9)
All Ref 2.7 (2.2–3.4) 7.4 (5.5–9.8)
Progressive CKD
eGFR ml/min per 1.73m2
4105 0.6 (0.5–0.8) 4.7 (0.3–69.4)
90–104 Ref 0.9 (0.7–1.2) 3.5 (0.5–26.0) Ref
75–89 1.0 (0.8–1.1) 3.5 (2.5–5.0)
60–74 2.8 (1.3–6.1) 9.3 (6.0–14.4)
45–59 3.0 (2.1–4.4) 4.8 (3.7–6.2) 10.1 (4.9–20.8) 31.4 (16.1–61.5) 4.7 (3.3–6.8)
30–44 3.3 (2.7–4.1) 3.4 (2.5–4.7) 9.8 (6.3–15.3) 68.7 (57.6–81.9) 6.4 (4.3–9.7)
15–29 0.5 (0.4–0.7) 3.1 (1.2–7.7) 9.4 (5.3–16.6) 38.6 (15.7–94.8) 8.9 (4.8–16.7)
All Ref 2.2 (1.9–2.7) 9.9 (6.7–14.5)
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; Ref, reference.
Pooled adjusted hazard ratios (95% confidence interval) for ESRD and acute kidney injury, and pooled adjusted odds ratios (95% confidence interval) for progressive CKD.
Shaded areas make up the combined reference groups.
Table 7 | High-risk cohorts
Albumin-to-creatinine ratio (mg/g) or dipstick (classes)
o10 Negative 10–29 Trace 30–299 (1+) X300 (X2+) All
ESRD, younger than 65 years of age
eGFR ml/min per 1.73m2
4105 1.1 (0.8–1.7) 1.4 (0.9–3.6)
90–104 Ref 2.6 (1.0–6.9) 10.5 (2.0–55.3) Ref
75–89 1.7 (0.8–3.8) 16.3 (2.3–119)
60–74 4.0 (2.0–7.7) 39.0 (10.3–148)
45–59 2.4 (1.4–4.2) 5.3 (2.3–12.2) 16.9 (4.7–60.5) 66.9 (20.1–222) 7.0 (4.3–11.6)
30–44 15.9 (1.9–133) 73.6 (20.5–264) 90.9 (27.6–299) 161 (26.3–989) 33.9 (14.6–78.9)
15–29 # 656 (172–2507) 792 (210–2982) 998 (105–9455) 223 (69.9–709)
All Ref 4.5 (2.4–8.5) 43.8 (16.4–117)
ESRD, older than 65 years of age
eGFR ml/min per 1.73m2
4105 0.0 (0.0–N) 20.6 (2.4–173)
90–104 Ref 0.0 (0.0–N) 15.5 (2.0–122) Ref
75–89 1.9 (0.6–5.9) 16.2 (3.1–84.6)
60–74 1.7 (0.6–4.7) 20.7 (9.4–45.8)
45–59 2.8 (1.1–7.2) 1.8 (0.5–6.4) 10.0 (5.5–18.1) 31.2 (10.9–89.5) 3.8 (2.5–5.8)
30–44 16.1 (6.7–38.8) 18.1 (7.5–43.6) 24.3 (9.3–63.4) 92.7 (46.3–186) 20.7 (14.0–30.6)
15–29 25.0 (3.2–196) 175 (42.5–718) 125 (43.0–363) 506 (158–1620) 146.6 (46.3–464)
All Ref 4.1 (2.5–6.8) 43.3 (13.0–145)
Abbreviations: #, insufficient number of events for reliable estimates; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; Ref, reference.
Pooled adjusted hazard ratios (95% confidence interval) for ESRD subdivided for age groups o65 and 465 years of age. Shaded areas make up the combined
reference groups.
98 Kidney International (2011) 80, 93–104
or ig ina l a r t i c l e RT Gansevoort et al.: Lower eGFR and higher albuminuria as risk factors for kidney outcomes
years of age (Supplementary Web appendix Table S10 online).
Similar findings were obtained for acute kidney injury
(Supplementary Web appendix Table S11 online) and progres-
sive CKD (Supplementary Web appendix Table S12 online).
Heterogeneity
eGFR albumin-to-creatinine ratio categories with signifi-
cant heterogeneity are shown in the Supplementary
Web appendix Table S10–12 online. Quantitative hetero-
geneity, rather than qualitative heterogeneity, was observed in
several categories, reflecting numerical differences in the
hazard ratios between cohorts, but the direction of the risk
was similar in all cohorts (increased risk with lower eGFR
categories and with higher albuminuria categories). However,
in all cohorts, the direction of the risk was similar (increased
risk with lower eGFR categories and with higher albuminuria
categories). Moreover, significant heterogeneity was limited
to the lowest eGFR and the highest albuminuria categories.
There was no significant heterogeneity in the groups with
eGFR of 45–60ml/min per 1.73m2 and in the groups with
microalbuminuria (albumin-to-creatinine ratio 30–299mg/g
or dipstick 1þ ), either in the general population or in the
high-risk population.
Meta-regression analysis was performed to test whether
the association between eGFR and albumin-to-creatinine
ratio with outcomes differed by the proportion of diabetic
participants within each high-risk cohort. The proportion of
diabetic participants was not significantly associated with the
hazard ratio for ESRD associated with eGFR (45 versus
95ml/min per 1.73m2; P¼ 0.58) or albumin-to-creatinine
ratio (30 versus 5mg/g; P¼ 0.31). Likewise, the proportion
of diabetic participants was not significantly associated
with the hazard ratio for progressive CKD associated with
eGFR (P¼ 0.57) or albumin-to-creatinine ratio (P¼ 0.96).
There were too few cohorts with sufficient events to allow
similar meta-regression models for acute kidney injury.
DISCUSSION
In this collaborative meta-analysis of nine general population
and eight high-risk cohorts, including a total of more than
1 million subjects, we found that lower eGFR and higher
albuminuria were associated with a higher risk for ESRD,
independent of each other and independent of traditional
CVD risk factors. A similar association of eGFR and
albuminuria was found with the risk for acute kidney injury
and for progressive CKD, although the relative hazards were
higher for ESRD.
The risk for ESRD based on eGFR and albuminuria have
been reported in a limited number of follow-up studies
from general population cohorts.20,22,28–30 The current meta-
analysis confirms these studies and extends the general-
izability of these data to other populations worldwide.
Furthermore, our collaborative meta-analysis includes 2201
ESRD outcomes, substantially more than the number of events
in reports of individual studies, thereby allowing evaluation of
the independent and joint associations of eGFR and albumi-
nuria with this outcome. In addition, we included data on
acute kidney injury and progressive CKD, other kidney disease
outcomes of clinical and epidemiologic interest.
We found similar patterns in studies that had data on
albumin-to-creatinine ratio and in the studies that only had
semiquantitative information available on dipstick protein-
uria. These findings suggest that measurement of dipstick
proteinuria is useful for risk stratification, despite being a less
precise measure of albuminuria. This is of importance
considering the lower cost of dipstick compared with
albumin-to-creatinine ratio measurement. However, studies
directly comparing dipstick testing with more accurate
albuminuria measurements are needed to investigate sensi-
tivity, specificity, and negative and positive predictive value to
make definite recommendations for screening. Also, it is
important to bear in mind that most studies had measured
albuminuria only once, thus raising questions regarding
reproducibility and chronicity of albuminuria. However, the
finding that a single urine test has significant prognostic
implication strengthens the conclusion that albuminuria
is an important risk factor. In addition, a single test may
underestimate rather than overestimate the risk associated
with albumin-to-creatinine ratio because of regression
dilution bias.31
The general pattern of a graded increase in relative risk for
the various kidney outcomes with higher albuminuria and
lower eGFR was observed in both cohorts at high risk for
CKD as well as cohorts derived from the general population.
Although the absolute incidence of ESRD was higher in the
high-risk population compared with the general population,
the increase in relative hazards for a lower eGFR and a higher
albuminuria was more pronounced in the general population
than the high-risk population. The consistency of our
findings in both cohorts with albumin-to-creatinine ratio
and dipstick proteinuria data, in both general population and
high-risk cohorts, and in both continuous and categorical
models for eGFR and albumin-to-creatinine ratio, demon-
strates the robustness of our findings. The finding of only
quantitative, but not qualitative heterogeneity, and that
heterogeneity was not observed in the categories of most
clinical interest, that is, eGFR 45–60ml/min per 1.73m2 and
albumin-to-creatinine ratio 30–299mg/g or dipstick 41þ ,
further underscores the strengths of our observations. Of
note, our meta-regression analyses showed that the associations
of eGFR and albuminuria with adjusted hazard rates for ESRD
and acute kidney injury outcomes were not related to the
proportion of diabetic subjects included in the various high-
risk cohorts. This provides no evidence for the assumption of
some investigators that diabetic and non-diabetic kidney
disease should be regarded as separate entities.
The statistical code that was sent to the participating
cohorts rendered output that did not permit computation of
a meta-analytic result for interactions. However, Tables 3 and
4 show that the pattern of higher relative hazards for ESRD
for a lower eGFR and for a higher albuminuria is less steep in
subgroups older than X65 than in those o65 years of
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age. The relationship of higher albuminuria with higher
unadjusted incidence rate of ESRD is comparable for both
age groups, but less steep with lower eGFR in the elderly
when compared with the young (Supplementary Web
appendix Table S3 online). The less steep relationship with
lower eGFR needs to be balanced against the higher incidence
rates in the older subgroup. Although in elderly the increase
in adjusted relative risk with lower eGFR is less than in the
young, the increase in unadjusted incidence rates is higher.
The age–eGFR interaction will be studied in depth in later
analyses by the CKD Prognosis Consortium.
The observed relative risk increase for ESRD with lower
eGFR is more pronounced than the relative risk increase
for all-cause and cardiovascular mortality, as described
separately.24 The hazard ratios for ESRD at eGFR 60, 45,
and 15ml/min per 1.73m2 were 3.69 (2.36–5.76), 29.3
(19.5–44.1), and 454.9 (112.4–1840.2), respectively, compared
with 1.16 (1.04–1.30), 1.49 (1.28–1.72), and 3.18 (2.45–4.14),
respectively, for all-cause mortality.25 Interestingly, the
increase in relative risk for higher albuminuria is also
substantially higher for ESRD compared with all-cause
mortality, with hazard ratios for ESRD at albumin-to-
creatinine ratio 30, 300, and 1000mg/g of 4.87 (2.30–10.3),
13.4 (5.49–32.72), and 28.4 (14.9–54.2), respectively,
compared with 1.16 (1.08–1.25), 1.51 (1.34–1.70), and
2.15 (1.80–2.58), respectively, for all-cause mortality.25 For
kidney outcomes, eGFR and albumin-to-creatinine ratios
were the strongest risk factors examined, often stronger than
age, which differs from all-cause mortality and cardiovascular
mortality where age is the dominant factor. The higher
relative risks for kidney outcomes than for mortality
likely reflect a greater specificity of association of eGFR
and albumin-to-creatinine ratio with these outcomes. The
implications of the more steep relationship of low eGFR and
high albuminuria with relative risk for ESRD than for
mortality should be considered in view of the relative low
incidence rates of the kidney outcomes. Lastly, these data are
not consistent with the suggestion by others that micro-
albuminuria is only a marker for increased CVD risk,11 as it
also indicates substantially increased risk for all kidney
outcomes examined.
A strength of this pooled analysis is that it includes data
on acute kidney injury and progressive CKD as well as on
ESRD. A disadvantage of limiting study of kidney outcomes
to only ESRD is that it will predispose to identification of low
eGFR values as the most important risk predictor, as the
decision to start renal replacement therapy is for a large part
based on eGFR. For clinical practice, however, it is also
important to identify risk predictors in subjects with
relatively preserved renal function, who may benefit from
early initiation of therapies to slow progression of CKD,
thereby delaying or even preventing ESRD and other
complications. Therefore, incident acute kidney injury and
progressive CKD were studied as earlier kidney outcomes
than ESRD. For acute kidney injury, the International
Classification of Diseases hospital discharge code 584 was
adopted as defining criterion. For progressive CKD, different
definitions have been used in the literature. Our definition
required loss of eGFR of more than 2.5ml/min per 1.73m2
per year (B3–5 times faster than the rate of renal function
decline in the general population21,30) and a final eGFR
during follow-up of p45ml/min per 1.73m2 (as it is widely
acknowledged that this threshold is of clinical significance).
Such a combination of a relative decrease and an absolute
threshold has been used before in epidemiological studies32
to increase specificity with a recognized loss of sensitivity. Of
note, the weaker associations of eGFR and albuminuria for
progressive CKD in comparison with the two other kidney
outcomes can be partially explained by misclassification of
the outcome and regression to the mean.
Some limitations of this meta-analysis should be men-
tioned. First, we included only a relatively limited number of
cohorts, and measurements of serum creatinine and albumi-
nuria were not centrally standardized across these cohorts.
The present analysis, however, is to the best of our knowledge
the largest and most comprehensive assessment of the
relation between eGFR, albuminuria, and kidney outcomes
yet performed. Second, no data on treatment effects could be
taken into account. Thus, it cannot be excluded that the
observed associations are influenced by the start of specific
treatments. However, if such treatment were effective in
preventing kidney disease progression, then it would be
expected to lead to an underestimation of the true relative
risk of low eGFR and high albuminuria for these outcomes.
Finally, we used a restrictive definition of progressive CKD,
and alternative definitions should be explored.
What do these findings mean for the current debate on the
definition and classification of CKD? First, as albuminuria is
a risk factor for kidney outcomes independent of eGFR and
conventional cardiovascular risk factors, this suggests that
albuminuria could be used for risk stratification at each level
of eGFR. A lack of multiplicative interaction means that
albuminuria has a similar relative risk at normal and low
eGFR. However, the baseline risk is higher at lower eGFR,
and hence the attributable risk will be higher at lower eGFR
for the same relative risk. Furthermore, as the risk for kidney
outcomes is higher for subjects with macroalbuminuria
(X300mg/g) than for subjects with microalbuminuria
(30–299mg/g), it seems prudent to define not only one, but
several thresholds for albuminuria to indicate increased risk
for kidney outcomes. Second, our finding that risk for kidney
outcomes is substantially higher in subjects with eGFR
30–45ml/min per 1.73m2 as compared with 45–60ml/min
per 1.73m2 suggests that it may be appropriate to subdivide
the present stage 3 CKD into two stages, as has been
proposed by others.33 Our finding of increased relative risk
for all three kidney outcomes for eGFR below 60ml/min per
1.73m2 and albuminuria (albumin-to-creatinine ratio
430mg/g or dipstick 4trace) are consistent with the
current thresholds for the definition of CKD. Some have
suggested age-specific thresholds, arguing that lower eGFR at
older age is a reflection of ageing11 and less associated with
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risk for adverse outcomes.34,35 Although we found a less steep
pattern of risk for kidney outcomes with lower eGFR in older
subjects compared with younger subjects, the pattern of
incidence rates was similar in older and younger subjects.
These data do not provide clear-cut evidence for the use of
age-specific eGFR thresholds to define CKD. In general,
decisions about the threshold levels for decreased GFR and
albuminuria to define and classify CKD should consider the
prevalence and absolute risk of decreased eGFR and
albuminuria, as well as relative risk.
In conclusion, our data show that both albuminuria and
eGFR are associated with all three kidney outcomes,
independent of each other and cardiovascular risk factors.
There was no evidence of multiplicative interaction between
eGFR and albuminuria. These findings provide a quantitative
basis for including these two kidney measures for risk
stratification, and CKD definition and staging.
MATERIALS and METHODS
Search strategy and study selection
In August 2009, we performed a systematic review of the
available literature to retrieve all general population cohorts
that might have information on the relation between eGFR
and/or albuminuria versus kidney outcomes. Details of the
search strategy can be found elsewhere.25 To be eligible
for inclusion, studies had to meet the following criteria:
(1) prospective, general population-based cohort study,
(2) information at baseline on eGFR as well as albuminuria
levels, (3) at least 1000 subjects included, (4) information on
at least one of the three kidney outcome measures, and (5) a
minimum of 50 events for that outcome measure. The reason
to require a minimum sample size is to ensure sufficient out
comes in the reference cell. Ultimately, 21 general population
cohorts met these eligibility criteria and were willing to
cooperate, of which 9 had data on kidney outcomes.20,28,36–42
We also included cohorts of individuals selected because of
high risk of CKD, including patients with cardiovascular
disease risk factors (such as hypertension and diabetes) or a
history of cardiovascular disease, because screening for CKD is
recommended in these groups. However, the associations
between eGFR and/or albuminuria and kidney outcomes may
differ between high-risk populations and the general popula-
tion. We analyzed eight high-risk cohorts that met the same
eligibility criteria as the general population cohorts.20,29,31,43–47
Study variables
In each cohort, subjects were subdivided according to eGFR
and albuminuria. GFR was estimated using the abbreviated
Modification of Diet in Renal Disease Study equation.48 Each
participating study was asked to standardize their serum
creatinine to Isotope Dilution Mass Spectrometry traceable
methods, but calibration methods were not uniform. As
recommended in clinical practice guidelines,3,33 albuminuria
was assessed as the urine albumin-to-creatinine ratio. If first
morning voids were not available, spot urine samples or
samples from 24 h urine collections were used. In studies in
which no quantitative albuminuria measurements were
available, data on urine protein-to-creatinine ratio47 or
dipstick testing for proteinuria20 were collected. eGFR and
albuminuria were measured at the onset of cohort studies.
Besides eGFR and albuminuria, information on demo-
graphic factors and cardiovascular risk factors were obtained
to compare baseline characteristics of the different cohort
studies and to adjust for confounding in multivariable
models. Cardiovascular disease history was defined as a
history of myocardial infarction, bypass grafting, percuta-
neous coronary intervention, heart failure, or stroke.
Hypertension was defined as systolic blood pressure
X140mmHg or diastolic blood pressure X90mmHg or
use of antihypertensive medication. Hypercholesterolemia
was defined as total cholesterol45.0mmol/l in the case of a
positive history of cardiovascular disease and as46.0mmol/l
in the case of a negative history of cardiovascular disease.
Diabetes mellitus was defined as fasting glucoseX7.0mmol/l
or non-fasting glucose X11.1mmol/l or use of glucose-
lowering drugs. Smoking habit was dichotomized as current
versus not current smoking.
Definition of kidney outcome measures
ESRD was defined as start of renal replacement therapy or
death coded as because of kidney disease other than acute
kidney injury. Acute kidney injury was defined as ICD-9 code
584 as primary or additional discharge code. Progressive
CKD was defined as an average annual decline in eGFR
during follow-up of at least 2.5ml/min per 1.73m2 per year
and a last eGFR value being less than 45ml/min per 1.73m2,
independent of the level of baseline eGFR. The average
annual decline in eGFR was calculated as last available eGFR
minus baseline eGFR divided by follow-up time (in years,
minimum two) between the two observations.
Statistical analysis
Our primary objective was to evaluate the associations of
eGFR and albuminuria, independently and jointly, on kidney
outcome measures. To maximize uniformity and minimize
bias, investigators from the cohort studies were invited to
collaborate in a pooled analysis following an a priori analytic
plan using standard statistical code that was provided by the
analytic team of the CKD Prognosis Consortium. All analyses
were conducted using Stata version 10 or 11 (Stata Corp,
College Station, TX), SAS version 9 (SAS Institute, Cary,
NC), or R version 2.9.2 (R Foundation for Statistical
Computing, Vienna, Austria). All data classification was
performed separately by analytic teams at the John Hopkins
Institute for Public Health, Baltimore, USA (KM, JC, and
BCA) and the University Medical Center Groningen,
Groningen, the Netherlands (MvdV, PEdJ, and RTG), and
differences were resolved by consensus.
For each study, a table was generated providing baseline
study characteristics. Cox proportional hazard models were
used to estimate the hazard ratios for ESRD and acute kidney
injury, and logistic regression analysis to estimate odds ratios
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for progressive CKD. These analyses were adjusted for age,
sex, race, and cardiovascular risk factors. Cardiovascular risk
factors taken into account were cardiovascular disease
history, smoking status, diabetes mellitus, systolic blood
pressure, and serum total cholesterol. The independent
continuous association of eGFR and of albuminuria with
risk for kidney outcomes was evaluated after adjusting for
each other and for CVD risk factors. eGFR and albumin-to-
creatinine ratio were modeled using linear splines with knots
at 45, 60, 75, 90, and 105ml/min per 1.73m2 and 10, 30, and
300mg/g, respectively. eGFR splines were also adjusted for
albuminuria (adjusted to an albumin-to-creatinine ratio of
5mg/g and dipstick negative), whereas albuminuria splines
were also adjusted for eGFR. For the continuous albuminuria
splines, only cohorts that had albumin-to-creatinine ratio
data were taken into account. eGFR 95ml/min per 1.73m2
and albumin-to-creatinine ratio 5mg/g were treated as the
reference points. These points were chosen, as they reflect the
anticipated low-risk groups. Interactions between eGFR and
both albuminuria and age were evaluated by likelihood-ratio
tests in individual studies, with albuminuria and age treated
as continuous variables.
For each outcome variable, information was generated for
the joint association of eGFR and albuminuria with kidney
outcomes. Eight eGFR categories were defined: o15, 15–29,
30–44, 45–59, 60–74, 75–89, 90–104, and X105ml/min per
1.73m2. These 15ml/min per 1.73m2 categories were chosen
to correspond to current CKD stages 1–5 and to evaluate
whether these stages require subdivision. For albumin-to-
creatinine ratio, we defined four categories: o10, 10–29,
30–299, and X300mg/g. These categories were chosen to
correspond to current definitions for microalbuminuria and
macroalbuminuria, and to evaluate whether the normoalbu-
minuria category should be subdivided. When information
on albumin-to-creatinine ratio was lacking, we used
information on dipstick proteinuria. As it has been shown
that the majority of subjects with a dipstick trace have high-
normal albuminuria, dipstick 1þ microalbuminuria, and
dipstickX2þ macroalbuminuria,49 we defined four dipstick
categories as: negative, trace, 1þ , and X2þ . We tested
whether combining cohorts with data on albumin-to-
creatinine ratio and cohorts with data on dipstick proteinuria
were valid. Unlike the mortality analyses,24,25 there were
insufficient kidney outcomes in the ‘optimal’ reference cell
(eGFR 90–104ml/min per 1.73m2 and albumin-to-creatinine
ratio o10mg/g) for the current analyses. Therefore, eGFR
X60ml/min per 1.73m2 and albumin-to-creatinine ratio
o30mg/g or dipstick negative/trace were chosen as the
reference cell, as present guidelines classify this group as
being free of CKD. For all of the 25 eGFR albumin-to-
creatinine ratio categories, information was obtained on the
distribution of subjects and the distribution of incident
events. For each study, the unadjusted incidence rate per 1000
person-years was calculated for each category. Hazard ratios
or odds ratios were estimated with adjustment for the
aforementioned cardiovascular risk factors. We conducted
complementary analyses where eGFR and albumin-to-
creatinine ratio were modelled continuously using the
same statistical models and adjustments. These models were
parameterized with eGFR¼ 95ml/min per 1.73m2 and
albumin-to-creatinine ratio¼ 5mg/g or eGFR¼ 95ml/min
per 1.73m2 and dipstick¼ negative/trace as the reference
point (hazard ratio or odds ratio¼ 1.0).
Pooled unadjusted incidence rates were obtained by
weighting the individual studies by the number of subjects
per category. Pooled estimates of the adjusted hazard ratios
and odds ratios, with 95% confidence interval, were obtained
from meta-analyses of random effects. Heterogeneity was
estimated using the w2-test for heterogeneity and the I2
statistic.50 Meta-analyses were conducted separately for
general population cohorts and high-risk cohorts. As there
were few participants (0.1%) with eGFR o15ml/min per
1.73m2, we only report results for participants with
eGFRX15ml/min per 1.73m2. A priori it was considered
that age could be an important effect modifier, and hence
results were also produced for age o65 and X65 years. This
age subdivision was chosen, as guidelines advise to screen for
CKD in subjects X65 years of age.
In all analyses, a P-value of o0.05 was considered to
indicate statistical significance.
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